AstraZeneca: gets EU approval for pancreatic cancer drug
(CercleFinance.com) - AstraZeneca said on Wednesday that a cancer drug it has developed with Merck has been approved in Europe for metastatic pancreatic cancer.
The drugmaker said that Lynparza has been approved by the European Commission for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate amongst the most common cancers. About 5%-7% of patients with metastatic pancreatic cancer have a germline BRCA mutation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The drugmaker said that Lynparza has been approved by the European Commission for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate amongst the most common cancers. About 5%-7% of patients with metastatic pancreatic cancer have a germline BRCA mutation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.